Yelin Lapidot Holdings Management Ltd. Has $14.09 Million Stock Holdings in MediWound Ltd. $MDWD

Yelin Lapidot Holdings Management Ltd. reduced its position in shares of MediWound Ltd. (NASDAQ:MDWD) by 5.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 763,069 shares of the biopharmaceutical company’s stock after selling 46,879 shares during the period. MediWound accounts for approximately 2.8% of Yelin Lapidot Holdings Management Ltd.’s holdings, making the stock its 9th biggest position. Yelin Lapidot Holdings Management Ltd. owned about 5.94% of MediWound worth $14,086,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Meitav Investment House Ltd. boosted its holdings in shares of MediWound by 825.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after buying an additional 260,116 shares during the period. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of MediWound during the 3rd quarter worth $1,042,000. Menora Mivtachim Holdings LTD. boosted its holdings in shares of MediWound by 348.8% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after buying an additional 61,039 shares during the period. Rosalind Advisors Inc. boosted its holdings in shares of MediWound by 84.0% during the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after buying an additional 341,993 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the period. 46.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MDWD has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $35.00.

MediWound Price Performance

Shares of MediWound stock opened at $16.80 on Friday. MediWound Ltd. has a fifty-two week low of $14.90 and a fifty-two week high of $22.50. The firm has a fifty day moving average price of $16.88 and a two-hundred day moving average price of $17.60. The company has a market cap of $215.88 million, a PE ratio of -8.00 and a beta of 0.21.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. The company had revenue of $1.87 million during the quarter. Analysts expect that MediWound Ltd. will post -2.75 earnings per share for the current fiscal year.

MediWound Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.